Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.

Exp Hematol. 2013 Jun;41(6):547-557.e2. doi: 10.1016/j.exphem.2013.02.008. Epub 2013 Feb 19.

2.

Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.

Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, Fang SH, Lu YB, Hu H, Wei EQ, Zhang WP.

Eur J Pharmacol. 2012 Jan 15;674(2-3):163-70. doi: 10.1016/j.ejphar.2011.11.017. Epub 2011 Nov 19.

PMID:
22119381
3.

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3.

4.

Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT, Chini EN.

Clin Cancer Res. 2014 Jan 1;20(1):120-30. doi: 10.1158/1078-0432.CCR-13-0150. Epub 2013 Sep 11.

5.

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.

Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjørnelund J, Dawson KM, Dupuis M, Duchosal MA.

Blood. 2009 Apr 2;113(14):3276-86. doi: 10.1182/blood-2008-08-173369. Epub 2009 Feb 5.

6.

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5.

7.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

8.

Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis.

Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M, Yang S, Zhao Z, Lai Y, Anderson JL, Fan J, Im HJ, Chen D, Roodman GD, Xiao G.

J Biol Chem. 2013 Oct 18;288(42):30399-410. doi: 10.1074/jbc.M113.469973. Epub 2013 Sep 4.

9.

Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.

Yang P, Zhang L, Shi QJ, Lu YB, Wu M, Wei EQ, Zhang WP.

Pharmazie. 2015 Oct;70(10):650-5.

PMID:
26601421
10.

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.

Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, Adamia S, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M.

Clin Cancer Res. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11.

11.

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Tan B, Dong S, Shepard RL, Kays L, Roth KD, Geeganage S, Kuo MS, Zhao G.

J Biol Chem. 2015 Jun 19;290(25):15812-24. doi: 10.1074/jbc.M114.632141. Epub 2015 May 5.

12.

Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.

Pittelli M, Cavone L, Lapucci A, Oteri C, Felici R, Niccolai E, Amedei A, Chiarugi A.

Immunol Cell Biol. 2014 Feb;92(2):191-9. doi: 10.1038/icb.2013.85. Epub 2013 Nov 26.

PMID:
24275857
13.

Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.

Breton CS, Aubry D, Ginet V, Puyal J, Heulot M, Widmann C, Duchosal MA, Nahimana A.

Biochimie. 2015 Sep;116:141-53. doi: 10.1016/j.biochi.2015.07.012. Epub 2015 Jul 15.

PMID:
26188110
14.

Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo.

Formentini L, Moroni F, Chiarugi A.

Biochem Pharmacol. 2009 May 15;77(10):1612-20. doi: 10.1016/j.bcp.2009.02.017. Epub 2009 Mar 5.

PMID:
19426698
15.

Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.

Yang NC, Song TY, Chang YZ, Chen MY, Hu ML.

Biogerontology. 2015 Feb;16(1):31-42. doi: 10.1007/s10522-014-9528-x. Epub 2014 Aug 22.

PMID:
25146190
16.

NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.

Zhang XQ, Lu JT, Jiang WX, Lu YB, Wu M, Wei EQ, Zhang WP, Tang C.

Neuroscience. 2015 Apr 16;291:230-40. doi: 10.1016/j.neuroscience.2015.02.007. Epub 2015 Feb 12.

PMID:
25684751
17.

Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.

Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F, Chiarugi A.

J Biol Chem. 2010 Oct 29;285(44):34106-14. doi: 10.1074/jbc.M110.136739. Epub 2010 Aug 19.

18.

Nampt/PBEF/visfatin and cancer.

Bi TQ, Che XM.

Cancer Biol Ther. 2010 Jul 15;10(2):119-25. doi: 10.4161/cbt.10.2.12581. Epub 2010 Jul 3. Review.

PMID:
20647743
19.

Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.

Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, Bianchi G, Vigliarolo T, Nahimana A, Nencioni A, Raffaelli N, Bruzzone S.

Oncotarget. 2016 Jan 19;7(3):2968-84. doi: 10.18632/oncotarget.6502.

20.

Inhibition of pre-B cell colony-enhancing factor (PBEF/NAMPT/visfatin) decreases the ability of human neutrophils to generate reactive oxidants but does not impair bacterial killing.

Roberts KJ, Cross A, Vasieva O, Moots RJ, Edwards SW.

J Leukoc Biol. 2013 Sep;94(3):481-92. doi: 10.1189/jlb.1012527. Epub 2013 Jun 26.

PMID:
23804809

Supplemental Content

Support Center